ARTICLE

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates

Angiolo Pierantoni1, Maria Luisa Esposito1, Virginia Ammendola1, Federico Napolitano1, Fabiana Graziol1, Adele Abbate1, Mariarosaria del Sorbo1, Loredana Siani1, Anna Morena D’Alise1, Alessandra Taglioni3, Gemma Perretta3, Antonio Siccardi3, Elisa Soprana4, Maddalena Panigada4, Michelle Thom2, Elisa Scarselli1, Antonella Folgori1, Stefano Colloca1, Geraldine Taylor2, Riccardo Cortese1,2, Alfredo Nicosia1,2, Stefania Capone1 and Alessandra Vitelli1

Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory disease in infants and the elderly. No vaccine is presently available to address this major unmet medical need. We generated a new genetic vaccine based on chimpanzee Adenovirus (PanAd3-RSV) and Modified Vaccinia Ankara RSV (MVA-RSV) encoding the F, N, and M2-1 proteins of RSV, for the induction of neutralizing antibodies and broad cellular immunity. Because RSV infection is restricted to the respiratory tract, we compared intranasal (IN) and intramuscular (IM) administration for safety, immunogenicity, and efficacy in different species. A single IN or IM vaccination completely protected BALB/c mice and cotton rats against RSV replication in the lungs. However, only IN administration could prevent infection in the upper respiratory tract. IM vaccination with MVA-RSV also protected cotton rats from lower respiratory tract infection in the absence of detectable neutralizing antibodies. Heterologous prime boost with PanAd3-RSV and MVA-RSV elicited high neutralizing antibody titers and broad T-cell responses in nonhuman primates. In addition, animals primed in the nose developed mucosal IgA against the F protein. In conclusion, we have shown that our vectored RSV vaccine induces potent cellular and humoral responses in a primate model, providing strong support for clinical testing.

Molecular Therapy — Methods & Clinical Development (2015) 2, 15018; doi:10.1038/mtm.2015.18; published online 20 May 2015

INTRODUCTION

Human respiratory syncytial virus (HRSV) is a highly infectious member of the Paramyxoviridae family causing upper and lower respiratory tract infections in humans. Respiratory syncytial virus (RSV) infection in children causes ~12 million severe and 3 million very severe cases of lower respiratory tract infection (LRTI) worldwide.1 RSV infection is also recognized as a significant problem in older adults. Epidemiological evidence indicates that the impact of RSV in the elderly may be similar to nonpandemic influenza.2 No effective treatment is available and the only preventative measure is a humanized monoclonal antibody specific to the RSV fusion (F) protein (Palivizumab) administered as monthly injections during the RSV season to prevent lower respiratory infections and severe disease in high-risk infants. However, it does not prevent infection of the upper respiratory tract and is not recommended for use in healthy infants or the elderly.3 In addition, because of the high costs, Palivizumab is not extensively used worldwide. A major barrier to pediatric vaccine development has been the occurrence of enhanced respiratory disease (ERD) seen following natural RSV infection of naive infants that had been vaccinated earlier with a poorly protective formalin-inactivated RSV (FI-RSV).4,5 Although the mechanisms responsible for FI-RSV induced ERD are not clear, the most prevalent hypotheses, based mainly on preclinical data, are that FI-RSV induced antibodies with poor functional activity resulting in immune complex deposition and complement activation in the lungs, and/or induced Th2-biased T-cells.6-8 Based on the current knowledge, an RSV vaccine for infants would ideally induce: (i) neutralizing antibodies against the F protein for protection against lung infection;9 (ii) a Th1-biased cellular immunity to contribute to virus clearance and to prevent ERD; and (iii) mucosal immunity (IgA, IgG, and T-cells) to protect at the portal of virus entry.10 Clinical manifestation of RSV disease and the immune response to infection differ in infants and the elderly, suggesting that vaccines designed to protect these populations may require different attributes. Low levels of RSV-specific nasal IgA against F and G proteins were found to be a significant risk factor for RSV infection in adults10 and increasing evidence suggests that deficient RSV-specific T-cell responses contribute to susceptibility to severe RSV disease in older adults.11,12 Therefore, a protective vaccine for the elderly should primarily aim at increasing mucosal IgA and cellular immune responses.
Genetic vaccine approaches and, in particular, those based on replication deficient Adenovirus vectors can address all of these needs. So far, Adeno-vectored vaccines against HRSV have been mainly investigated in mice or cotton rats. Replication defective Adenovirus serotype 5 (Ad5) expressing the RSV F protein administered intramuscularly (IM) or intranasally (IN) or by a mixed modality of IM prime/IN boost has provided protection from RSV challenge in mice and cotton rats. Similarly, a gorilla-derived Adeno vector expressing the RSV F protein has been recently reported to be protective in mice and cotton rats after IM vaccination.

We have generated a new RSV vaccine candidate consisting of a synthetic, consensus-based sequence encoding a soluble F protein for the induction of neutralizing antibodies and the conserved N and M2-1 internal proteins, for the induction of a broader T-cell repertoire. This antigen was inserted in a replication incompetent chimpanzee Adenovirus (PanAd3), which is insensitive to pre-existing antiadenovirus antibodies present in the human population, and in Modified Vaccinia Ankara (MVA). We show here that a single IN or IM administration of PanAd3-RSV completely protected mice against RSV replication in the lungs and a single IN administration in cotton rats resulted in complete protective efficacy in the upper and in the lower respiratory tract for at least 3 months after vaccination without signs of enhanced pulmonary pathology. We also show that IM administration of a MVA vector encoding the same RSV antigen protects cotton rats from LRTI in the absence of neutralizing antibodies and without potentiation of pulmonary pathology.

An improved regimen based on heterologous prime/boost with PanAd3 administered IN or IM and MVA injected IM was also tested in nonhuman primates (NHP). Vaccinated macaques exhibited strong and Th1 biased T-cell responses which were directed against all the vaccine antigens, and neutralizing antibody titers greater than the previously reported threshold for protection of infants. Moreover, IN vaccination elicited mucosal IgA.

These preclinical data strongly support the clinical development of the vectored vaccine and suggest that different combinations of routes and regimens can be exploited for the development of RSV vaccines for the pediatric and the elderly populations.

RESULTS

Vaccine antigen structure, expression and vectored delivery

We designed a synthetic HRSV antigen composed of three viral proteins: F, N, and M2-1 (F0ΔTM–N–M2-1), which was encoded by a single open reading frame with a self-cleaving Foot and Mouth Disease virus 2A sequence between F and N sequences. A short sequence encoding a flexible linker was inserted between the N and the M2-1 sequences to facilitate folding (Figure 1a). The transmembrane and cytoplasmic regions of the F protein were deleted for efficient secretion of a soluble form of the F protein. The synthetic gene was codon-optimized for expression in human cells. Mature N–M2-1 fusion protein was detected by Western blot (WB) in cell lysates of DNA transfected HeLa cells (Figure 1b). The high molecular weight precursor F–N–M2-1 was barely detectable indicating efficient 2A-driven self-processing. Consistent with this observation, the soluble F protein was found in the medium of transfected cells with an apparent molecular weight of ~170kDa on a nonreducing SDS–PAGE gel, compatible with F protein trimers, and was recognized by the conformation sensitive neutralizing antibody mAb 13 (ref. 22) (Figure 1c). When the soluble F protein was run on a reducing SDS–PAGE, two fragments were revealed consistent with the size of F1 and F2, indicating that the protein was correctly processed at the furin-cleavage sites (see Supplementary Figure S1).

The F0ΔTM–N–M2-1 RSV vaccine antigen was inserted into two different recombinant viral vectors: a replication-defective chimpanzee Adenovirus, PanAd3 (PanAd3-RSV) and a replication-defective poxvirus, Modified Vaccinia Ankara RSV (MVA-RSV).

PanAd3-RSV is immunogenic and protects BALB/c mice against HRSV infection

To test the immunological potency of the novel RSV vectored vaccines a dose–response immunization study with PanAd3-RSV was conducted in BALB/c mice (Figure 2a). T-cell responses were

\[
\begin{align*}
\text{RSV} & : \text{F0ΔTM–N–M2-1} \\
\text{N} & : \text{M2-1} \\
\end{align*}
\]

Figure 1 The RSV vaccine antigen. (a) Schematic diagram of the synthetic DNA fragment used to express the RSV antigens by PanAd3 and MVA vectors. 2A self-cleavage site derived from Foot and Mouth Disease virus sequence; (b) WB analysis of total cell lysates from HeLa cells not transfected (nt) or transfected with an expression plasmid bearing the RSV antigen (RSV) and revealed using a monoclonal antibody against M2-1 (mAb 8). The arrows indicate the bands corresponding to the MW of the unprocessed precursor or to the fused internal proteins N and M2-2; (c) WB analysis of supernatants of Hela cells transfected with an expression plasmid encoding the RSV antigen (RSV) or the F0ΔTM protein (F0), after migration on nonreducing SDS–PAGE. A band of ~170kDa indicated by the arrow was revealed by the monoclonal antibody mAb 13 raised against the F protein which is consistent with a soluble F trimer.
measured by IFN-γ ELIspot using three mapped CD8+ epitopes (F51-66, F85-93, and M2-182-90). As expected, given the presence of a strong K1-restricted immunodominant epitope in the M2-1 protein, the T-cell response was mainly directed to the peptide M2-1 82-90 (see Supplementary Figure S2). The PanAd3-RSV vector showed strong T-cell responses over a wide range of doses, with 5 out 14 mice vaccinated with 10^4 viral particles (vp) still having RSV epitope-specific responses above the background.

Because IN delivery can induce local immunity in the respiratory tract at the portal of virus entry,21 we compared T-cell and antibody responses in animals immunized by IM or IN delivery of 5 × 10^7 vp of PanAd3-RSV. IM immunization with PanAd3-RSV elicited stronger T-cell responses in the spleen compared with IN immunization (geometric mean = 3,224 versus 976 SFC/10^6 splenocytes), whereas comparable T-cell responses were observed in the lungs (8,300 versus 5,600 SFC/10^6) (Figure 2c). Low levels of serum antibodies to the strong Kd-restricted immunodominant epitope in the M2-1 protein, F protein were induced 4 weeks after vaccination and unexpectedly, antibody titers were higher following IN vector delivery (Figure 2d). We next challenged BALB/c mice with HRSV, 4 weeks after IM or IN vaccination with 5 × 10^7 vp of PanAd3-RSV, to explore the effect of the strong Adeno-induced T-cell component in the absence of protective levels of neutralizing antibodies (Figure 3d). Following a high dose challenge with 4 × 10^5 plaque forming units (pfu) of HRSV, strain A2, vaccinated mice were fully protected against virus replication in the lung (Figure 3a). Importantly, none of the vaccinated animals showed eosinophils (Figure 3c) or increased number of leukocytes in bronchoalveolar lavages (BAL) compared with HRSV-infected, unvaccinated controls (Figure 3b). As expected, low levels of RSV-specific serum IgG were detected in both vaccinated groups at the day of the challenge, and levels of neutralizing antibodies were below the limit of detection in IM vaccinated mice and were log, 4 in IN vaccinated mice (Figure 3d). Following the high dose challenge, all mice lost weight following RSV infection; however, the onset of weight loss was more rapid in vaccinated mice than in controls and less pronounced in IN than in IM vaccinated mice (Figure 3e). IN delivery also showed a better efficacy profile also in terms of lung pathology relative to IM vaccinated mice. In fact, IM delivery induced higher scores of alveolitis (A) compared to either IN vaccinated mice or control animals (Figure 3f).

PanAd3-RSV induces safe and durable protective efficacy in cotton rats

The cotton rat model is considered to be informative for the safety and efficacy profile of HRSV vaccines because (i) the animals can be infected with clinical isolates of HRSV; (ii) the virus replicates in both the upper and lower respiratory tract; and (iii) vaccination with FI-RSV vaccine primes for ERD-like hallmarks, such as alveolitis, following RSV challenge.24 Groups of cotton rats were immunized with single IM administrations of 10^7, 10^8 and 5 × 10^7 vp or with single IM administrations of 5 × 10^7 and 5 × 10^8 vp of PanAd3-RSV. Another group received 10^7 pfu MVA-RSV IM. All groups were challenged IN with RSV, 7 weeks after vaccination. Control groups included unvaccinated animals, a group earlier infected with RSV and a group vaccinated with FI-RSV as an internal control for enhanced pulmonary pathology. All animals vaccinated IM with PanAd3-RSV developed good levels of neutralizing antibodies (nAbs = Log, 6–7), comparable to those induced by an earlier RSV infection (Figure 4a). As observed in BALB/c mice, IN vaccination elicited higher titers of nAbs (Log, 8–9) respect to IM vaccination at the same dose. In contrast, none of the animals vaccinated with MVA-RSV showed detectable levels of neutralizing antibodies 7 weeks after vaccination. As shown in Figure 4b, all vaccinated animals except one outlier in the group receiving the lowest dose IN were fully protected against viral replication in the lung. In addition, mucosal vaccination with PanAd3-RSV at doses of 10^6 and 5 × 10^7 effectively blocked RSV replication in the upper respiratory tract (Figure 4b). In contrast, although systemic vaccination strongly reduced viral replication in the nose, it did not achieve complete protection even at high doses. These data support the importance of mucosal immunity in preventing RSV infection. Interestingly, a single IM dose of MVA-RSV was also fully protective in the lung, despite the lack of induction of circulating neutralizing antibodies, suggesting a role for other immune effector mechanisms in MVA-mediated protection. We further explored the durability of the protective efficacy given by the single IN dose of 5 × 10^7 vp PanAd3-RSV. Three groups of cotton rats were vaccinated IN with PanAd3 and challenged 3, 7, or 12 weeks after vaccination. All animals were fully protected from infection in the upper and lower respiratory tract and showed quite stable neutralizing antibody titers over the whole observation period (Figure 4c). As expected, RSV infection in FI-RSV vaccinated cotton

**Figure 2** Immunological potency of PanAd3-RSV and MVA-RSV in BALB/c mice. (a) T-cell responses in spleens of animals vaccinated IM with different doses (vp) of PanAd3-RSV measured by IFNY ELIspot. Symbols show individual mouse data, expressed as IFNY spot forming cells (SFC)/million splenocytes, calculated as the sum of responses to the three immunodominant epitopes (F51-66, F85-93, and M2-1 82-90) corrected for background. Horizontal lines represent geometric mean; (b) T-cell responses in spleens of animals vaccinated IM with different doses (pfu) of MVA-RSV. (c) T-cell responses in spleen (left) or lung (right) of mice vaccinated with 5 × 10^7 vp of PanAd3-RSV IM or IN. Data are expressed as IFNY SFC/million splenocytes or pulmonary lymphocytes; (d) Anti-F protein IgG endpoint titers in sera from IM and IN vaccinated animals. Responses in a, b, c, and d were measured 4 weeks after vaccination.
Viral vectored vaccines for RSV
A Pierantoni et al.

Figure 3  RSV challenge in BALB/c mice. Vaccination with PanAd3-RSV at 5 × 10^8 vp dosage was performed IM or IN, and 4 weeks later the animals were challenged with 4 × 10^7 pfu of HRSV, strain A2. (a) RSV titer in lung homogenates 5 days postchallenge. Total (b) and differential (c) inflammatory cell counts in BAL from vaccinated and unvaccinated mice, either uninfected or RSV infected (controls) 6 days after RSV challenge. Single animal's data are shown in (b), while mean + SD is shown in (c); Eo, Eosinophils; L, lymphocytes; Mo, monocytes; Neu, neutrophils; (d) RSV-specific IgG endpoint titer (filled symbols plotted on left y axis, individual mice) and RSV neutralization antibody titer (gray bar plotted on right y axis, pooled sera) in vaccinated and control animals. Limit of detection (LOD) for both assays is indicated by dashed lines; (e) Groups of five mice were vaccinated and challenged as described earlier and their body weight monitored for 12 days after challenge. Data are expressed as the percentage of weight loss compared to initial weight, and are presented as mean and SD for each group; (f) Mean + SD of pathology score recorded in each experimental group for bronchiolitis (gray bars) and A (black bars). Bronchiolitis (thickness of cells surrounding the bronchiole or blood vessel) and A (number of inflammatory cells in the air spaces) were scored on a scale from 0 to 3, and multiplied by the proportion of lung section affected on a scale from 0 to 4, giving a maximum score of 36 per mouse lung for each of the two parameters. Mean + SD of pathology score recorded in each experimental group for bronchiolitis (gray bars) and A (black bars) are shown.

PanAd3-RSV prime/MVA boost induces strong B- and T-cell responses in CD1 mice

Outbred CD1 mice were used to test the immunological potency of various combinations of PanAd3 prime/MVA boost regimens as they are genetically heterogeneous and therefore represent a better model than inbred mice for human MHC heterogeneity. CD1 mice were administered IN or IM with 10^8 vp of PanAd3-RSV, followed by IM boosting with 10^7 pfu of MVA-RSV, 4 weeks later. Spleen and lung RSV-specific T lymphocytes were analyzed 3 weeks after the boost by IFN-γ ELISpot. Both regimens induced broad and potent IFN-γ T-cell responses which recognized all three RSV vaccine antigens to varying extents (Figure 5a, b). Pulmonary RSV-specific T-cells producing IL-4, which have been correlated with enhanced disease in animal models and in humans, were not detected in the lung of PanAd3-RSV/MVA-RSV immunized animals, indicating that the response was skewed toward a Th1 phenotype (Figure 5a).

Higher anti-F IgG titers were induced by IN PanAd3-RSV prime, but overall the levels of neutralizing antibodies were comparably high (up to log2 12) in both prime/boost regimens (Figure 5c). Furthermore, a competition assay showed that antibodies induced by vaccination with PanAd3-RSV IN/MVA-RSV IM were able to compete with Palivizumab, thus binding antigenic site II or overlapping epitopes (Figure 5d).

In conclusion, PanAd3/MVA induced potent humoral and cellular immunity in CD1 mice.

Heterologous prime/boost regimens are immunogenic in NHP

Data gathered in the different rodent models strongly supported the IN route as an immunogenic, protective, and safe route for the vectored RSV vaccine. However, it is generally recognized that genetic vaccines are often less effective in large animals than in rodents. Therefore, the immunogenicity of prime/boost vaccine regimens was explored in primates, which are a more relevant model for the development of a human vaccine. A crucial aspect of IN administration is the modality of vaccine delivery into the nasal cavity. Two different IN delivery systems were explored: instillation and IN spray. The spray device (Accuspray system, Becton Dickinson, Franklin Lakes, NJ) was chosen because it generates an aerosol of an average drop size of 30 µm, to limit penetration into the lower respiratory...
Three groups of three Cynomolgus macaques (Macaca fascicularis) were immunized with $5 \times 10^8$ vp PanAd3-RSV by: (i) IM injection, (ii) IN instillation of drops and (iii) IN spray. As shown in Figure 6a, T-cell responses in the blood were higher in animals inoculated with the spray device than those inoculated by IN instillation. Therefore, this group of animals and the group that received the prime IM were boosted 8 weeks later by IM injection of $1 \times 10^8$ pfu of MVA-RSV. T-cell responses after vaccination were measured by IFN-\( \gamma \) neutralizing antibody titers in vaccinated and control animals expressed as the serum dilution (log2) reducing plaques by 60% compared to controls. Sera were collected at study week 7 at the time of challenge. Bars represent group mean + SD. (b) RSV titers in lung homogenates and nasal tissue collected 5 days after RSCH challenge. Data are expressed as RSV plaque forming units per gram of tissue (pfu/g). Bars represent group mean + SD. (c) RSV neutralizing titers (filled symbols plotted on right y-axis, individual animals) and virus titers in lung and nasal tissue (black and gray bars plotted on left y-axis, group mean + SD) at week 3, 7, and 12 after IM vaccination with $5 \times 10^8$ vp PanAd3-RSV. (d) Histological analysis of lung sections 5 days after RSV challenge. Formalin-fixed, paraffin-embedded lung sections were stained with hematoxylin and eosin. Four parameters of pulmonary inflammation were evaluated: peribronchiolitis (PB), perivasculitis (PV), interstitial pneumonia (IP), and alveolitis (A). Slides are scored blind on a 0–4 severity scale, and values are then converted to a 0–100% histopathology score. The dashed line (set at 5%) represents a threshold of IP and A pathology score considered not compatible with ERD. Bars show group mean + SEM.

DISCUSSION

Our strategy to develop an effective and safe candidate RSV vaccine was based on: (i) the design of a novel immunogen including B- and T-cell antigens; (ii) the choice of a validated vector delivery platform capable of eliciting humoral and cellular immunity in humans; and (iii) the demonstration of consistent immunogenicity, safety, and efficacy of different mucosal and systemic regimens of administration in rodents and NHPs. The RSV F glycoprotein is a conserved target of nAbs, including Palivizumab (Synagis), which also contains human T-cell epitopes. The N and M2–1 internal proteins are highly conserved between RSV strains and are known to be a source of T-cell epitopes in humans.1,8 We therefore designed an artificial fusion protein including an N-terminal F protein followed by a picorna virus 2A consensus cleavage sequence and by the N and M2–1 coding sequences separated by a flexible gly-ser linker to allow for proper independent folding of the two polypeptides. The intervening 2A sequence led to efficient cotranslational cleavage of the polyprotein releasing the F protein from the rest of the N–M2–1 fusion protein. Although we did not
Viral vectored vaccines for RSV
A Pierantoni et al.

Figure 5 Cellular and humoral response to PanAd3-RSV/MVA-RSV vaccination in CD1 mice. (a) T-cell responses, measured by ELISpot in spleen (left) or lung (right) of mice vaccinated with 10^8 vp of PanAd3-NSV IM or IN, and boosted IM 4 weeks later with MVA-RSV at 10^7 pfu. For each mouse, the sum of responses to four overlapping peptide pools spanning the complete RSV vaccine antigen subtracted of DMSO background was calculated. Data are expressed as IFN-γ (closed symbols) or IL4 (open symbols) SFC/million splenocytes or pulmonary lymphocytes; (b) magnitude and breadth of IFN-γ lung lymphocyte response to individual peptide pools covering RSV transgene (Fa, Fb, M, and N) and to DMSO, the peptide diluent, in individual mice within each immunization group (indicated at the bottom of the graph); (c) Anti-F protein IgG endpoint titer (filled symbols plotted on left y axis, individual mice) and RSV neutralization titer (black bar plotted on right y axis, pooled sera) in vaccinated animals. Horizontal lines in a and c represent geometric mean values. All responses shown in a, b, and c were measured 3 weeks postboost; (d) Inhibition of Synagis (Palivizumab) binding to F protein by pooled sera from mice immunized with PanAd3-RSV and control preimmune sera. Synagis binding (percentage of ELISA signal without competing sera) is plotted as a function of the dilution of competing pooled sera.

We showed that both IN and IM delivery of the F–N–M2-1 antigen by a single administration of the replication incompetent chimpanzee Adenovirus PanAd3 or by PanAd3 prime/MVA boost induced high levels of RSV nAbs in all the animal species tested, apart from BALB/c mice. Acknowledging the fact that comparison of antibody levels among different labs deserves some caution, the neutralizing antibody titers of Log2 ≥ 8, which are above the threshold of RSV nAb titres of Log2 ≥ 6 that have been associated with a reduced risk of hospitalization in infants.20

In addition to neutralizing antibodies, RSV-specific CTLs may also play a crucial role in protection from RSV disease as suggested by studies in infants where decreased frequencies of CD8+ T-cells correlated with increased severity of RSV disease12 or by studies in which children with compromised cell-mediated immunity shed virus for a prolonged time and have increased disease.33,34 Furthermore, an age-related decline of RSV-specific cellular immunity has been described in older adults, whereas a similar decline was not observed for influenza-specific T-cell responses. These observations suggest that the elderly have a reduced capacity to generate or maintain RSV-specific T-cells and this defect may be correlated with their increased susceptibility to RSV disease. Therefore, boosting cellular immunity to RSV could be beneficial in reducing the burden of severe disease in the elderly. We showed that the vectored RSV vaccine induced a broad, strong, and Th1-biased cellular immune response in all the animal species tested. A Th1-skewed T-cell response in BALB/c mice can prevent allergic inflammation and eosinophilia in the lung post-RSV challenge. On the other hand, RSV-specific CTLs are known to be induced by recombinant protein or VLP in adjuvant, and three- to fivefold higher than those required for protective immunity in the cotton rat model. In NHPs the genetic vaccine induced nAb titers of Log2 ≥ 8, which are above the threshold of RSV nAb titres of Log2 ≥ 6 that have been associated with a reduced risk of hospitalization in infants.20
contribute to immune-mediated pathology. In this inbred model, the immunodominant K\(^{b}\) restricted M2-182-90 response has an extreme effector phenotype and can produce immunopathology when present at high frequencies.\(^{37}\) Furthermore, the strong CD8\(^{+}\) response induced in BALB/c mice may be responsible for the low levels of F-specific and neutralizing antibodies. The rapid, but transient weight loss seen in vaccinated BALB/c mice in our studies and the increased lung pathology seen in IM vaccinated BALB/c mice are most likely because of a high titer virus inoculum encountering the strong M2-182-90 CD8\(^{+}\) response in the absence of neutralizing antibodies.

To provide experimental support to our hypothesis further experiments are needed, such as a lower titer RSV challenge, or the introduction of mutations in the CTL epitope M2-182-90 as described by Vallbracht et al.\(^{38}\) who showed significant reduction in weight loss after RSV infection without an impact on viral clearance.

In this study we demonstrated that vaccination of cotton rats with MVA-RSV by IM delivery was also completely protective in the lung, despite the absence of serum neutralizing antibodies; these animals
had no signs of A or IP but showed higher scores of peri-bronchiolar infiltrates in the lung which could be interpreted as a consequence of the critical role played by cell mediated immunity in clearing the virus in the absence of nAbs.

Overall, the protective immunity given by the vectored vaccines in the absence of neutralizing antibodies in the two rodent models of HRSV infection was not associated to enhanced lung pathology: in BALB/c mice the vaccine did not induce pulmonary eosinophilia after challenge and in cotton rats it was protective without inducing pulmonary pathology.

In contrast to BALB/c mice, PanAd3-RSV induced good levels of neutralizing antibodies even at low doses in cotton rats. All the tested doses and routes conferred full protection in the lung, with no associated pathology. An important role for mucosal immunity in protective efficacy from RSV infection emerged from the cotton rat challenge studies where only the animals that received PanAd3-RSV IN were completely protected against RSV infection in both the upper and the lower respiratory tract. Further experiments are needed to find the dose of vaccine conferring partial protection in the lung and to assess any associated pulmonary pathology. Nevertheless, to confirm and expand our notions on safety, immunogenicity, and efficacy of the vectored vaccine, studies are ongoing in a model of natural infection, such as young sero-negative calves.

Evidence from human clinical trials has shown that heterologous chimpanzee Adeno prime/MVA boost vaccine regimen induces potent, broad, and durable T- and B-cell immunity.39 Here we demonstrate, consistently, that priming with PanAd3-RSV and boosting with MVA-RSV were very efficient at inducing high nAb titers as well as potent and broad RSV-specific T-cell responses in NHPs. T-cell responses were distributed over all vaccine antigens confirming that the strategy of including the conserved viral proteins N and M2-1 effectively augmented vaccine immunogenicity. Interestingly, the neutralizing antibody titers were similar between IM and IN vaccinated animals but only IN primed animals showed circulating RSV-specific IgA-secreting cells, suggesting that nasal delivery elicited mucosal immunity.

In conclusion, we have presented evidence that a new RSV antigen delivered by genetic vaccine vectors using a combination of routes and heterologous prime/boost regimen can induce a full array of immune responses that could address the different attributes required to protect infants and the elderly.

MATERIALS AND METHODS

Vaccine antigen

The human RSV expression cassette contained consensus sequences of F, N, and M2-1. HRSV F, N, and M2-1 sequences were downloaded from the NCBI database. Protein sequences were chosen among RSV subgroup A for F, specific for the F protein.22 mRNA constructs for RSV F, N, and M2-1 were purchased from JPT Peptide Technologies GMBH. HRSV peptide pools covering the complete sequence of the vaccine antigens F, N, and M2-1 were tested for Tet repressor expression by WB analysis. The stability of Tet repressor expression cassette and G418-resistance gene. The protocol for generating the PanAd3 cell line followed essentially that published by Matthews et al.48 In brief, HEK 293 cells were transfected with an expression vector containing a cassette encoding the Tet repressor under control of the human phosphoglycerate kinase-1 promoter, and the G418-resistance gene. Single clones were selected by growing the transfected cells in the presence of 1 mg/ml G418 in culture medium. Single clones were amplified and tested for Tet repressor expression by WB analysis. The stability of Tet repressor expression in the selected clone was tested up to passage 63. PanAd3 vectors grown in these cells were purified by cesium chloride gradients and stored in Buffer A195.44

MVA vector

MVA, attenuated by ~500 passages in primary chick embryo fibroblasts (CEF),46 was used to create a recombinant MVA carrying the HRSV genes. The HRSV genes were subcloned into the TPG shuttle vector.46 The so-generated transfer vector TPG-HRSV drives the HRSV antigen expression using the vaccinia P7.5 early/late promoter and enhanced green fluorescent protein (EGFP) expression using the synthetic promoter p5. The production of the recombinant virus was obtained by a previously described method46 based on in vivo recombination between homologous sequences (Flank-I and -2 regions) present in both the acceptor virus MVA-RED virus46 and the plasmid transfer vector TPG-HRSV. Primary CE cells were then infected/ transfected with MVA-Red, a recombinant MVA carrying the HcRed1-1 gene and with the TPG-HRSV plasmid. The virus-containing cell lysate derived from infection/transfection was diluted 1:100 and used to infect fresh CEF in the presence of 1 μmol/l cytchalasin D (Sigma-Aldrich, St. Louis, MO). Infected cells, collected 24 hours p.i. by trypsinization, were washed, and kept on ice. Green cells were either bulk- or single cell-sorted by a Becton Dickinson FACSVantage SE flow cytometer (Becton Dickinson, San José, CA). EGFP fluorescence (excited at 488 nm) was detected using a 530/30 nm bandpass filter. HcRed1-1 fluorescence (excited at 633 nm) was detected using a 660/20 nm bandpass filter. Sorted cells were seeded onto CEF monolayers in microplate cultures to produce virus-containing cell lysate. Finally, markerless recombinant viruses (MVA-HRSV) were cloned by terminal dilution screening by whole plate fluoroimaging (Typhoon FLA 9000, GE Healthcare, Uppsala, Sweden), cloned again by terminal dilution and expanded in CEF by conventional methods.

In vitro expression and WB

HeLa cells were transfected with 4 μg of pVJ-RSV plasmid using Lypofectamine (Invitrogen, CA). Extracts were prepared 48 hours after transfection using TEN buffer (20 mmol/l Tris pH 7.5, 150 mmol/l NaCl, 1 mmol/l EDTA pH 8, 1% Triton X100 and protease inhibitors). Nuclei and cell debris were spun out by centrifugation at 7,500 x g, 60 minutes at 4°C. Glycerol was added to supernatants to 10% and stored at –20°C. Expression of the antigen proteins in the cell extracts was assessed by running the samples in reducing SDS–PAGE and WB with the monoclonal antibody mAb 8, specific for the M-2 protein.22 Supernatants were collected 24 hours after infection. Expression of F protein was analyzed by running supernatant samples in nonreducing SDS–PAGE and WB with mAb 13, specific for the F protein.22

Peptides and proteins

CD8+ immunodominant peptides in BALB/c mice (F51-66, F85-93, and M2-182–90) were purchased from JPT Peptide Technologies GMBH. HRSV peptide pools covering the complete sequence of the vaccine antigens F, N, and M2-1,
consisting of 15-mer sequences with 11 amino acids overlap were purchased from JPT. The 269 peptides were dissolved in 100% DMSO and arranged in four pools as follows: pool M (46 peptides), pool N (95 peptides), pool Fa (N terminal half of F protein, 64 peptides), and pool Fb (C terminal half, 64 peptides). Recombinant (r)F protein from strain HRSV A2 was purchased from SinoBiologics, Beijing, China.

Immunogenicity studies in mice and macaques

All experimental procedures were approved by institutional review boards and were performed in accordance with national and international laws and policies. The ethical committee of the Italian Ministry of Health approved this research. Animal handling procedures were performed under anesthesia and all efforts were made to reduce animal numbers and minimize suffering.

Six-week-old female BALB/c and CD1 mice were purchased from Charles River (Calco, Lecco, Italy). For IM immunizations, the intended dose of PanAd3-RSV or MVA-RVS vectors in a total volume of 100 µl was injected bilaterally in quadriceps muscles (50 µl/site). For IN administration, the intended dose of PanAd3-RSV in 20 µl volume was administered by delivering 10 µl in each nostril. Mice were euthanized after vaccination/challenge as specified in the figure legends to test immune responses. For experiments involving prime/boost, the two vaccinations were spaced 4 weeks apart, and animals were euthanized 2 weeks after boosting. All antisera were performed under isoflurane anesthesia.

Splenocytes were isolated with standard techniques. To isolate infiltrating lymphocytes from the lungs of immunized mice, the organs were minced and incubated in DMEM/10% FBS with Collagenase Type I (2100,000 U/g, Gibco) for 60 minutes at 37 °C on an orbital shaker. All tissues were then homogenized, filtered through a sterile 70 µm Nylon cell strainer and lymphocytes were isolated by density gradient centrifugation (Ficoll-Paque). White cells were collected from the interface, and finally treated with ACK (8A10492, Gibco) to lyse red blood cells.

Female Cynomolgus macaques (Macaca fascicularis) from a purpose-bred colony housed at the IBCM primate facility (Enea-Casaccia, Rome, Italy) were distributed in groups of three animals each, equivalent for mean body weight. 

During handling the animals were anesthetized by injection of 10 mg/kg ketamine hydrochloride. The injected dose was 5×10^6 PFU for adenoviral vectors, and 2×10^9 PFU for MVA. IM vaccination was performed in the deltoid muscle in 0.5 ml volume. For IN immunization, the same PanAd3-RSV dose was suspended in 0.2 ml total volume and 0.1 ml volume was administered per nostril as either drops or sprayed using the Accuspray (Becton Dickinson) device. To administer the vaccine with Accuspray, manufacturer recommendations for correct head position and device angle were followed.

Sedated animals were kept with their head upright, and the tip of the device was inserted in the nostril keeping the syringe as horizontal as possible to orient the spray cloud correctly toward the nasal cavity. Active inspiration was not required for correct nasal deposition, thus sedation does not interfere with the spray cloud correctly toward the nasal cavity. Active inspiration was not required for correct nasal deposition, thus sedation does not interfere with the orientation of the spray cloud correctly toward the nasal cavity.

INtranasal cytokine staining and FACS analysis

The contribution of CD4 and CD8 subsets to the overall IFNγ T-cell response was analyzed in macaque PBMCs by IFNγ intracellular staining and FACS analysis exactly as described earlier.8

EX vivo F-specific IgG and IgA ASC ELISPOT

Multiscreen HTS MSIP510 plates (Millipore, MA, United States) were preacti-vated with 50 µl/well of 70% ethanol, washed with sterile water, and coated overnight with either 500 ng/well of recombinant F protein (SinoBiologicals, Beijing, China) diluted in 50 mmol/l NaHCO3 coating buffer, or with 150 ng/well of anti-IgG or anti-IgA capture mAbs diluted in PBS as a positive control. After washing, five times with PBS, plates were blocked with R10 (RPMI, 10% FBS, 200 mmol/l L-Glutamine, 50ng/ml Streptomycin, 50U Penicillin, 1M HEPES) culture medium for 30 minutes at room temperature. Freshly isolated PBMC were plated in R10 at 500,000 and 250,000 cells/well in duplicate (250,000/well and 125,000/well for total IgA and IgG, respectively) and left overnight at 37°C, 5% CO2. Plates were developed by subsequent incubation with biotinylated anti-IgG and anti-IgA detection mAbs, followed by streptavidin–alkaline phosphatase conjugate and finally with BCIP/NBT-plus till blue spots emerged. All antibodies and ELISPOT reagents were from Mabtech, Sweden. Plates were analyzed by an A.ELVIS automated plate reader and responses were expressed as the number of antigen-specific IgG or IgA ASC per million PBMCs.

Humoral response analysis in mice and macaque sera

RSV-F protein-specific antibody levels were measured by enzyme-linked immunosorbent assay (ELISA). Nunc-MaxiSorp (SIGMA) 96-well plates were coated at 4°C overnight with 0.5 µg/100 µl of rF (SinoBiologicals) in 0.05 M NaHCO3 buffer. Data are expressed as endpoint titers calculated from 1 hour absorbance readings, defined as the highest dilution of sample giving an OD1.4 reading greater than three SD above the mean of preimmune samples. Levels of HRSV-specific IgG in mouse sera were determined using a lystate of HRSV A2 infected fetal calf kidney cells as described earlier.44 A lysate of mock-infected cell pellets was used as negative control.

Neutralizing antibody titers were measured by a FACS-based assay which relies on a recombinant RSV expressing GFP,46 a generous gift from Prof. Mark E. Peeples, Nationwide Children’s Hospital, Columbus, OH, United States. The assay was performed essentially as described earlier.26 In brief, HEP-2 cells were plated (5×104 cells/100 µl each well) in 96-well plate(s) and incubated for 2 hours at 37 °C, 5% CO2. Serial dilutions of heat-inactivated sera were incubated with RSV expressing GFP (0.1 multiplicity of infection (MOI)) for 1 hour at 37 °C with 5% CO2 in 100 µl DMEM 7% FCS and then added to the cells and left for 20–22 hours at 37 °C in 5% CO2, 36% relative humidity. The extent of viral replication was determined by a plaque reduction assay using the HRSV, A2 strain and calculated using a 50% reduction of the virus control.

BALB/c challenge study

Specific-pathogen-free, female BALB/c mice, weighing ∼20 g were obtained from Charles River UK. Mice (N = 15/group) were vaccinated either IM with 5×106 PFU of PanAd3-RSV in a volume of 50 µl, or PanAd3 expressing irrelevant antigens; or IN under isoflurane general anesthesia. Mice were bled from the tail vein, 2 and 4 weeks after vaccination and were challenged IN with 4×104 pfu of the A2 strain of HRSV, in a volume of 50 µl, under isoflu-rane general anesthesia, 4 weeks after vaccination. Groups of five mice were weighed daily for 12 days following HRSV challenge. Groups of five mice were sacrificed 5 days postchallenge, and HRSV titres in lung homogenates were determined by plaque assay on Vero cells. Further groups of five mice were sacrificed 6 days after challenge, and their lungs subjected to BAL with 1 ml of 12 mmol/l lidocaine in PBS, and then fixed in 10% buffered formalin. Cytocentrifuge preparations of BAL cells were stained with May–Grunwald Giemsa and differential cell counts of 300 cells per slide were made under oil immersion microscopy. Lung sections were stained with hematoxylin and eosin and histopathological lesions were scored as the score for each of three different lung lobes/mouse. The extent of peribronchiolar and perivascular inflammation was scored on a scale from 0 to 3 depending on the thickness of cells surrounding the bronchiole or blood vessel multiplied by the proportion of lung section showing peribronchiolar inflammation on a scale from 0 to 4, giving a maximum bronchiolitis score of 36 for each mouse lung. The extent of A was scored on a scale of 0 to 3 depending on the number of inflammatory cells in the air spaces multiplied by the proportion of lung section with A on a scale from 0 to 4, giving a maximum A score of 36 for each mouse lung.
Statistical analysis

Statistical analysis and graphs were made using GraphPad Prism version 5.02 for Windows (GraphPad Software, San Diego, CA, http://www.graphpad.com). As data were not always normally distributed, a two-tailed Mann–Whitney (nonparametric) test was used to compare two groups. Statistically significant differences are shown as follows: *P* = 0.01–0.05, **P** < 0.01, ***P*** < 0.001, and ****P*** < 0.0001. Statistical analysis was applied to immunological or pathology data when comparing groups vaccinated at the same dose via different routes.

**ACKNOWLEDGMENTS**

The authors acknowledge Andrea Stardelli (CRIS, Cagliari, Italy) for bioinformatic help in the design of the vaccine antigens, Sigmovir Biosystems Inc (Rockville, MD, United States) for expert assistance in the cotton rat studies, Mark Peeples (The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States) for kindly providing the recombinant RSV expressing GFP virus, Jean-François Toussaint (GSK Vaccines, Rixensart, Belgium, and Ann-Muriel Steff (GSK, Laval, Canada) for critical reading of the manuscript. BBSRC Institute Strategic Programme on Livestock Viral Diseases at The Pirbright Institute and MRC grant MR/J014648/1. G.T. is an Jenner Investigator. A.V., R.C., and A.N. are named inventors on patent applications covering periviral bronchiolitis (inflammatory cell infiltration around the bronchioles), perivascularitis (inflammatory cell infiltration around the small blood vessels), IP (inflammatory cell infiltration and thickening of alveolar walls), and A (cells within the alveolar spaces). Slides were scored blind on a 0–4 severity scale. The scores were subsequently converted to a histopathology scale 0–100%.

**REFERENCES**

1. Nair, H, Simoes, EA, Rudan, I, Gessner, BD, Azziz-Baumgartner, E, Zhang, JS et al; Severe Acute Lower Respiratory Infections Working Group (2013). Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 381: 1380–1390.

2. Falsey, AR (2013). Editorial commentary: respiratory syncytial virus: a global pathogen in an aging world. Clin Infect Dis 57: 1078–1080.

3. TheImPact-RSV Study Group. (1998). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531–537.

4. Fulginiti, VA, Eller, JJ, Sieber, OF, Joyner, JW, Minamitani, M and Meiklejohn, G (1969). Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccine controls using the statistics program “plqrd.manual.entry”.

5. Kapikian, AZ, Mitchell, RH, Chanock, RM, Shvedoff, RA and Stewart, CE (1969). An epidemic of respiratory syncytial virus infection in children previously vaccinated with an inactivated RSV virus vaccine. Am J Epidemiol 89: 435–448.

6. Kim, E, Okada, K, Beeler, JA, Crim, RL, Piedra, PA, Gilbert, BE et al. (2014). Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J Virol 88: 509–510.

7. Johnson, TR, Rangel, D, Graham, BS, Bough, DE and Gall, JG (2014). Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther 22: 196–205.

8. Anderson, R, Huang, Y and Langley, JM (2010). Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiol 5: S85–S62.

9. Vitelli, A, Quirion, MR, Lo, CY, Misplon, JA, Grabowska, AK, Pierantoni, A et al. (2013). Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. PLoS One 8: e55435.

10. Piedra, PA, Jewell, AM, Cron, SG, Atmar, RL and Glezen, WP (2003). Correlates of immune complexes in respiratory syncytial virus (RSV)-associated hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21: 3479–3482.

11. Fang, J, Qian, JJ, Yi, S, Harding, TC, Tu, GH, VanRoeys, M et al. (2005). Stable antibody expression at therapeutic levels using the 3A peptide. Nat Biotechnol 23: 594–590.

12. Taylor, G, Stott, EJ, Furze, J, Ford, J and Sopp, P (1992). Protective epitopes on the protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol 73(Pt 1): 2217–2223.

13. Woodland, DL (2013). Intranasal vaccination. Viral Immunol 26: 125.

14. Boukhvalova, MS and Blanco, JC (2013). The cotton rat and Sigmodon hispidus model of respiratory syncytial virus infection. Curr Top Microbiol Immunol 372: 143–175.

15. Gerds, V, Litte-von den Hurk, Sv, Griebel, P and Bablik, LA (2007). Use of animal models in the development of human vaccines. Future Microbiol 2: 667–675.

16. Brand, P, Häusinger, K, Meyer, T, Scheuch, G, Schulz, H, Selzer, T et al. (1999). Intrapulmonary distribution of deposited particles. J Aerosol Med 12: 275–284.

17. Chaiwatponsakorn, S, Eford, RP, Collins, PL, Eford, PM and Peeples, ME (2011). Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretagged state is triggered by exposure to low-molarity buffer. J Virol 85: 3968–3977.

18. McElhaney, JS, Chen, M, Leung, S, Graepel, KW, Du, X, Yang, Y et al. (2013). Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340: 1113–1117.

19. Smith, G, Raghunandan, R, Wu, Y, Liu, Yi, Massare, M, Nathan, M et al. (2002). Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 7: e50582.

20. Swanson, KA, Settembre, EC, Shaw, CA, Dey, AK, Rappuoli, R and Mandl, CW et al. (2011). Structural basis for immunoactivation with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 108: 9619–9624.

21. Prince, GA, Horswood, RL and Chanock, RM (1985). Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55: 517–520.

22. Laara, G, Ambrosy, SL, van den Hurk, SV, Margesin, JD, Helbert, ER, van Mansfeld, J, Van Boven, P, Van Der Plas, M and De Vries, M (1980). Impaired immune response in cotton rats after intranasal respiratory syncytial virus infection by respiratory syncytial virus. Pediatr Infect Dis 28: 867–873.

23. Fishaut, M, Tubergen, D and McIntosh, K (1980). Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 96: 179–186.

24. Hall, CB, Powell, KR, MacDonald, NE, Gala, CL, Menegus, ME, Sufkin, SC et al. (1986). Respiratory syncytial virus infection in children with compromised immune function. N Engl J Med 315: 77–81.
Viral vectored vaccines for RSV
A Pierantoni et al.

35. Lee, FE, Walsh, EE, Falvey, AR, Liu, N, Liu, D, Divekar, A et al. (2005). The balance between influenza- and RSV-specific CD4 T cells secreting IL-10 or IFN-gamma in young and healthy-elderly subjects. Mech Ageing Dev 126: 1223–1229.

36. Olson, MR and Varga, SM (2007). CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 179: 5415–5424.

37. Cannon, MJ, Openshaw, PJ and Askonas, BA (1988). Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 168: 1163–1168.

38. Vallbracht, S, Jessen, B, Mrusek, S, Enders, A, Collins, PL, Ehl, S et al. (2007). Influence of a single viral epitope on T cell response and disease after infection of mice with respiratory syncytial virus. J Immunol 179: 8264–8273.

39. Capone, S, D’Alise, AM, Ammendola, V, Colloca, S, Cortese, R, Nicosia, A et al. (2013). Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 12: 379–393.

40. Edgar, RC (2004). MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5: 113.

41. Waterhouse, AM, Procter, JB, Martin, DM, Clamp, M and Barton, GJ (2009). Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189–1191.

42. Graham, FL, Smiley, J, Russell, WC and Nairn, R (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59–74.

43. Matthews, DA, Cummings, D, Evelegh, C, Graham, FL and Prevec, L (1999). Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. J Gen Virol 80 (Pt 2): 345–353.

44. Evans, RK, Nawrocki, DK, Isopi, LA, Williams, DM, Casimiro, DR, Chin, S et al. (2004). Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 93: 2458–2475.

45. Di Lullo, G, Soprana, E, Panigada, M, Palini, A, Agresti, A, Comunian, C et al. (2010). The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. J Virol Methods 163: 195–204.

46. Di Lullo, G, Soprana, E, Panigada, M, Palini, A, Erfle, V, Staib, C et al. (2009). Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. J Virol Methods 156: 37–43.

47. Capone, S, Naddeo, M, D’Alise, AM, Abbate, A, Grazzini, F, Del Gaudio, A et al. (2014). Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. Mol Ther 22: 1039–1047.

48. Taylor, G, Stott, EJ, Hughes, M and Collins, AP (1984). Respiratory syncytial virus infection in mice. Infect Immun 43: 649–655.

49. Hallak, LK, Spillmann, D, Collins, PL and Peeples, ME (2000). Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74: 10508–10513.

50. Chen, M, Chang, JS, Nason, M, Rangel, D, Gall, JG, Graham, BS et al. (2010). A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. J Immunol Methods 362: 180–184.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/